ReviewJournal of clinical medicine2025
Advancements and Innovations in Keratoconus Management: A Review of Current Practices.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Outcomes and Complications After INTACS Implantation in Keratoconus: A Systematic Review.Journal of clinical medicine · 2026Review
- Case Report: Effective management of acute corneal hydrops with concurrent nystagmus and retinitis pigmentosa: combination of deep lamellar corneal suturing and anterior chamber gas injection.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keratoconus is a potentially blinding condition characterized by progressive thinning and steepening of the cornea, leading to visual impairment due to irregular astigmatism and myopia. While the exact pathophysiology is still unknown, it is believed to involve genetic, environmental, and cellular factors. Treatment options for keratoconus have significantly expanded over the past few decades. Historically, glasses were the primary means of managing mild cases, whereas rigid gas permeable contact lenses were used in moderate to advanced diseases; yet the latter were rarely tolerated by patients with steep cones, in which full-thickness corneal transplantation was often performed. However, a variety of innovative treatments have been introduced in the past decades. Corneal collagen cross-linking (CXL) has revolutionized the field by halting the progression of keratoconus through creating new covalent bonds between individual corneal fibers. Custom, soft, and scleral contact lenses have improved visual outcomes for many patients. Additionally, surgical interventions such as intrastromal ring segments and Bowman layer transplantation have provided alternatives for visual restoration and postponing a potential keratoplasty. Furthermore, innovative cellular and pharmacological KCN treatments are on the horizon, awaiting clinical trials. This review article aims to provide a comprehensive overview of the current treatment options for keratoconus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.